title: [Evaluation of carbetocin (pabal) efficacy in the prevention of the postpartum hemorrhage in women after cesarean section--preliminary report].
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy of carbetocin in prevention of PPH in women after cesarean section.
  
  
  METHODS
  We enrolled 60 patients who had undergone cesarean section in tertiary referential center, Department of Perinatology, Medical University of Lodz, Poland, between January and June 2008. Each patient obtained a single 100 microg dose of carbetocin intravenously during cesarean section, immediately after the delivery of the baby and prior to the delivery of the placenta. We evaluated postoperative blood parameters in 2 and 12 hours after the operation, the proportion of patients requiring additional uterotonic agents and adverse events in the whole population and in the group of women with high risk of PPH.
  
  
  RESULTS
  58.1% of patients underwent emergency and 41.3% elective cesarean section delivery. The risk factor of PPH was identified in 38 women (63.3%). The results of this study indicate that carbetocin produces rapid and long-lasting uterine tone. A small drop in mean hemoglobin and hematocrit levels 2 and 12 hours after the operation was observed. 15% of patients required the use of additional uterotonic agents. In the group of women with high risk of PPH, carbetocin appeared to be effective in 79% of the patients. Only 11.4% of patients had minor adverse events.
  
  
  CONCLUSIONS
  Carbetocin appears to be an effective new drug in the prevention of postpartum hemorrhage, not only among women undergoing cesarean section but also in the group of women with PPH risk factors.
authors.affiliation: Pracownia Medycznych i Srodowiskowych Zagrozen Ciazy, Klinika Perinatologii, I Katedry Ginekologii i Połoznictwa, Uniwersytetu Medycznego w Lodzi. j.kalinka@csk.am.lodz.pl
authors.forename: Jarosław
authors.initials: J
authors.lastname: Kalinka
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Lipińska
authors.forename: Dariusz
authors.initials: D
authors.lastname: Sosnowski
authors.forename: Wojciech
authors.initials: W
authors.lastname: Wiliński
authors.forename: Michał
authors.initials: M
authors.lastname: Skoczylas
authors.forename: Marcin
authors.initials: M
authors.lastname: Serafin
authors.forename: Maria
authors.initials: M
authors.lastname: Prośniewska
authors.forename: Paweł
authors.initials: P
authors.lastname: Krajewski
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Laudański
mesh_terms: D000328:Adult; D002585:Cesarean Section / Q000009:adverse effects*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007430:Intraoperative Care; D010121:Oxytocin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011044:Poland; D019106:Postoperative Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006473:Postpartum Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D011247:Pregnancy; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D010121:Oxytocin; C020731:carbetocin